BamSEC and AlphaSense Join Forces
Learn More

Stoke Therapeutics Inc. – Material Contracts

NASDAQ: STOK    
Share price (3/18/26): $31.02    
Market cap (3/18/26): $1.835 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.15
from 10-K 4 pages Stoke Therapeutics, Inc. (“Company”) Non-Employee Director Compensation Policy Approved as of September 9, 2024 (The “Approval Date”) as Amended Through March 11, 2026
12/34/56
EX-10.2
from 8-K 7 pages Change of Control Severance Agreement
12/34/56
EX-10.1
from 8-K 12 pages Executive Employment Agreement
12/34/56
EX-10.3
from 10-Q 5 pages March 16, 2025 Arthur Tzianabos
12/34/56
EX-10.2
from 10-Q 5 pages March 16, 2025 Ian F. Smith
12/34/56
EX-10.1
from 10-Q 13 pages March 16, 2025 via E-Mail Edward Kaye Re: Terms of Resignation
12/34/56
EX-10.2
from 10-Q 94 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed License and Collaboration Agreement by and Between Stoke Therapeutics, Inc. and Biogen International Gmbh Dated as of February 14, 2025
12/34/56
EX-10.1
from 10-Q 4 pages Stoke Therapeutics, Inc. (“Company”) Non-Employee Director Compensation Policy Approved as of September 9, 2024 (The “Approval Date”) Amended as of February 12, 2025
12/34/56
EX-10.20
from 10-K 3 pages Stoke Therapeutics, Inc. Certain Cash Director Fees - Form of Irrevocable Payment Election
12/34/56
EX-10.3
from 10-Q 13 pages Stephen Tulipano Email: Re: Terms of Separation Dear Stephen: This Letter Confirms the Agreement (“Agreement”) Between You and Stoke Therapeutics, Inc. (The “Company”) Concerning the Terms of Your Separation and Offers You the Separation Compensation We Discussed in Exchange for a General Release of Claims and Covenant Not to Sue. 1
12/34/56
EX-10.2
from 10-Q 7 pages Change of Control Severance Agreement
12/34/56
EX-10.1
from 10-Q 11 pages Executive Employment Agreement
12/34/56
EX-10.12
from 10-K 46 pages Lease Agreement
12/34/56
EX-10.3
from 10-K 40 pages 1. Purpose. the Purpose of This Plan Is to Provide Incentives to Attract, Retain, and Motivate Eligible Persons Whose Present and Potential Contributions Are Important to the Success of the Company, and Any Parents, Subsidiaries, and Affiliates That Exist Now or in the Future, by Offering Them an Opportunity to Participate in the Company’s Future Performance Through the Grant of Awards. Capitalized Terms Not Defined Elsewhere in the Text Are Defined in Section 29. 2. Shares Subject to the Plan
12/34/56
EX-10.1
from 10-Q 13 pages Stoke Therapeutics, Inc. Scientific Advisory Board Agreement
12/34/56
EX-10.1
from 10-Q 140 pages License and Collaboration Agreement by and Between Stoke Therapeutics, Inc. and Acadia Pharmaceuticals Inc. January 9, 2022
12/34/56
EX-10.13
from 10-K 13 pages Stoke Therapeutics, Inc. Scientific Advisory Board Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Amendment to Sublease
12/34/56
EX-10.1
from 10-Q 37 pages Lease Agreement
12/34/56
EX-10.1
from 10-Q 134 pages 139 Main Street Cambridge, Massachusetts Lease Summary Sheet
12/34/56